Cipla Limited (CIPLA) — Board Meeting | 13 May 2025(2 announcements)

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Board Meeting 🟡 Notable Neutral 📄 PDF

The board approved the appointment of Joshi Apte & Associates as cost auditor for FY 2025-26, BNP & Associates as secretarial auditor for five years until March 2030, and B S R & Co. LLP as statutory auditor for a first term of five years starting after the 90th AGM in FY 2026-27, subject to regulatory compliance.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

Cipla reported consolidated revenue of ₹27,547.62 crores for FY2025, up 32% YoY, with net profit after tax at ₹5,269.20 crores and EPS of ₹65.29. The board proposed a total dividend of ₹16 per share (final ₹13 + special ₹3), record date June 27, 2025. Cash flow from operations reached ₹6,820.81 crores. Litigation over NPPA demands (~₹2,011 crores) is expected to resolve favorably without provisioning.

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day